Pfizer's stock has plummeted as the company faces challenges in its COVID-19 vaccine sales and other products. The company's revenue projections for 2024 are below estimates, and its earnings estimates for FY24 are reduced. Pfizer's acquisition of cancer drug developer SGEN has received regulatory approvals. The stock closed FY19 at around $260 billion EV, with dramatically reduced FY24 earnings estimates. Pfizer's mRNA COVID jabs and Paxlovid sales are expected to fall by 35% next year, contributing to the stock reaching a five-year low. The company's board of directors has approved an increase in the quarterly cash dividend per share.
$PFE | Pfizer Board Of Directors Approves Increase In Quarterly Cash Dividend From $0.41 To $0.42 Per Share https://t.co/Z9unBUmSAl
Pfizer: Why its FY2024 downgrade has Wall Street wary https://t.co/H48DUf4C9c by @AnjKhem
$PFE about to go negative on the day...
$PFE has received all required regulatory approvals to complete its acquisition of cancer drug developer $SGEN. @MadisonMills22 discusses: https://t.co/yRfMBob5NT
Pfizer stock plummets as people turn away from Covid boosters https://t.co/CEHIBsvH4z https://t.co/CEHIBsvH4z
How Pfizer is fortifying for growth beyond COVID products https://t.co/Dq7JLxzIl8 https://t.co/gw89BaxY2U
What's Driving the Pfizer Tumble? - The Rebel's Edge https://t.co/rb9BfEn9Uj
Pfizer Stock Can't Catch a Break, But That Doesn't Mean It's Broken @davidmoadel https://t.co/BP9rRoUe8C $PFE
$SGMO 8k out: https://t.co/PVGb8iN9WH Ladies and gentlemen, I believe $PFE, esp after today's earnings, cannot afford to sit on this #hemophiliaA gene therapy opportunity. Updated 4-year phase I/II data from #ASH23, p3 in mid-24. https://t.co/btntrX1xjJ
$PFE EV closed FY19 at ~ $260B. Top line doubled from $40B to $80B in FY21 and $100B in FY22 on COVID vaccine. Consensus is now at $60B for FY24. Dramatically reduced FY24 earnings estimates are north of $2 per share, ~ double the $1.25 reported in FY19. EV today ~ $170B https://t.co/BpjQFHFSO2
$PFE (-6.1% pre) Pfizer's Tumble Steepens As $SGEN Seagen Guidance Update Disappoints - IBD https://t.co/TgKo67gChX
Oops @pfizer now says sales of its mRNA Covid jabs and Paxlovid will fall another 35% next year. The stock is at a five-year low. @AlbertBourla, the world’s (former) favorite veterinarian, managed to blow maybe $30-40 billion in Covid profits. Well played, sir. $pfe https://t.co/nPKZTQwzf6
🔴 PFIZER PROJECTS 2024 REVENUE OF $58.5 BILLION TO $61.5 BILLION, BELOW ESTIMATED $62.94 BILLION